To characterize members of the Mycobacterium abscessus complex, with an emphasis on the correlation between species identification and clarithromycin associated genetic polymorphisms that contribute to inducible and constitutive macrolide resistance. PCR and sequencing analysis was used to elucidate the subspecies, erm(41) genotypes and the presence of rrl mutations. M. abscessus subsp. massiliense was the dominant subspecies (70.2 %), followed by M. abscessus subsp. abscessus (23.8 %) and M. abscessus subsp. bolletii (5.9 %). The majority of M. abscessus and M. bolletii isolates possessed T28 erm(41) sequevar and were inducibly resistant to clarithromycin. All M. massiliense carried the truncated erm(41) and were largely clarithromycin-susceptible (98.3 %). Constitutive resistance involving rrl mutations was rare and seen in only 2 isolates (2.2 %). Subspecies identification was insufficient to predict clarithromycin susceptibility and required the genetic resistance to be determined via sequencing. In our context, rrl mutations were uncommon and may not be an essential test.
The Mycobacterium abscessus complex consists of three closely-related rapidly-growing-mycobacteria (RGM): M. abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. abscessus subsp. bolletii (hereafter referred to as M. abscessus, M. massiliense and M. bolletii, respectively). They are often associated with chronic pulmonary infections in hosts with predisposing factors such as underlying structural lung disease, cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease (COPD), and prior tuberculosis [1] . Extra-pulmonary sites of infection have also been described such as skin and soft tissue infections (SSTIs), central nervous system infections, bacteremia, and ocular infections [2] .
Overall, members of the M. abscessus complex are the most frequently isolated RGM in Singapore, and represent approximately 35 % of clinical infections with non-tuberculous mycobacteria [3, 4] . Ordinarily, they are not considered to be transmitted from individual to individual, however an outbreak involving the respiratory spread of M. massiliense in cystic fibrosis patients has been described [5] . Putative virulence factors have been elucidated in the M. abscessus members. This includes the ESX-3 (of the type VII secretion pathway) which is conserved in all mycobacterial species and has been shown to be important in M. abscessus pathogenesis and virulence during infection [6] . M. massiliense and M. bolletii carry mammalian cell entry (MCE) genes, which contribute to pathogenesis but are absent from strains of M. abscessus subsp. abscessus [7] . However, current knowledge does not fully elucidate the pathogenic mechanisms of M. abscessus complex infections in humans yet.
Treatment regimens are combination-based, relying on a macrolide (clarithromycin) and an aminoglycoside such as amikacin along with another active antimicrobial such as a b-lactam (imipenem, meropenem, cefoxitin) [8] . Drug therapy is lengthy (ranging from 2 weeks to several months) and more often than not, unsuccessful [1] . Treatment failure is attributed to both constitutive and inducible antimicrobial resistance that is prevalent in the M. abscessus complex; in particular, lower rates of clinical, radiological, and microbiological responses have been reported in association with clarithromycin resistance seen in M. abscessus when compared to M. massiliense [9] . Phenotypically, constitutive clarithromycin resistance is characterized by high minimal inhibitory concentration (MIC) values at day 3 of culture whilst inducible resistance is observable at day 7 up to day 14. Therefore, as recommended by the Clinical and Laboratory Standards Institute (CLSI) M24-A2 guidelines [10] , prolonged incubation of up to fourteen days should be carried out for the tested isolates.
Inducible macrolide resistance is conferred by ribosomal methylase gene, erm(41) [11] . Functionality of the erm(41) gene is further complicated by sequevars that carry a T-to-C substitution at position 28 of the gene. The C28 erm(41) sequevar is non-functional, hence susceptible to clarithromycin upon phenotypic testing [11, 12] . Typically, inducible resistance mediated by erm(41) is observed in M. abscessus and M. bolletii. On the other hand, M. massiliense usually possesses a 274 bp deleted, non-functional erm(41) gene copy and exhibits marked susceptibility to clarithromycin, and inducible resistance to clarithromycin has not been observed during prolonged incubation [11, 12] . Constitutive resistance to macrolides occurs due to spontaneous point mutations at positions 2058 or 2059 of the 23S rRNA (rrl) gene [12, 13] .
Treatment response rates to clarithromycin-based therapy are higher in patients with M. massiliense lung disease due the predominance of the deleted non-functional erm(41) than those infected with M. abscessus [14] . Within the M. abscessus group, M. bolletii is a relatively rare pathogen but has proven to be highly resistant to clarithromycin [15] . Accordingly, the 3 subspecies respond differently to macrolide therapy [8, 14] due to their erm(41) genotypes and interplay with rrl mutations. In this study, we characterized members of the M. abscessus complex, correlating the species identification, clarithromycin associated genetic polymorphisms, and phenotypic susceptibility testing results.
The study was performed at a tertiary acute care hospital of 1250 beds. Members of the M. abscessus complex in this retrospective study were obtained during the time period of December 2013 -June 2016, from routine mycobacterial culture requests for which susceptibility testing was also performed. Duplicate samples from the same patient and sample site were excluded. Susceptibility testing was carried out when the isolate was presumed to be of clinical significance based on: (i) positive culture results from at least two separate expectorated sputum samples; (ii) positive culture results from bronchoalveolar lavage (BAL); (iii) lung biopsy; and (iv) biopsy or fluid specimens from other sterile or soft tissue sites. BAL, sputum, lung biopsies, and pleural fluid were categorized as respiratory samples whilst non-respiratory specimens consisted of abscess, blood, urine, bone marrow, tissue, wound swab and skin biopsy, corneal scraping, joint fluid, pericardial fluid and peritoneal fluid ( Table 1) . As the ethics approval did not cover retrieval of antibiotic treatment or patient clinical histories, we did not have information on prior patient exposure to macrolides.
Isolates were first identified through Microflex LT Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-ToF) instrument (Bruker Daltonik GmbH, Leipzig, Germany) and broadly assigned within the M. abscessus complex. UltraClean Microbial DNA Isolation Kit (Mo Bio, Carlsbad, USA) was used to extract mycobacterial genomic DNA. The rpoB and hsp65 genes were employed for subspecies identification [16, 17] . The following primer pairs were used: 5¢-GACGACATCGACCACTTCGG-3¢ and 5¢-GGGGTCTCGATC GGGCACAT-3¢ for rpoB, and 5¢-A TCGCCAAGGAGATCGAGCT-3¢ and 5¢-AAGGTGCCGC GGATCTTGTT-3¢ for hsp65. Amplicon sequencing was performed. Phylogenetic trees were built separately for hsp65 and rpoB using MegAlign software (DNASTAR, Madison, WI) to determine the identification of isolates to subspecies level. The analysis was performed using bootstrap analysis with 1000 re-samplings and 111 seed with reference sequences. Reference hsp65 and rpoB sequences were derived from whole genome sequence data of M. bolletii strain MM1513 (GenBank: CP009447), M. massiliense strain GO06 (GenBank: CP003699.2) and M. abscessus strain FLAC054 (GenBank: CP014961).
The minimal inhibitory concentrations (MICs) of clarithromycin, cefoxitin, imipenem, amikacin, linezolid, moxifloxacin, doxycycline, and ciprofloxacin were determined using broth micro-dilution using Sensititre RGMYCO plates (TREK Diagostics, Cleveland, OH). Plates were incubated at 37 C and readings were taken at days three and fourteen. Interpretations of susceptible, intermediate, or resistant were made according to the CLSI M24-A2 guidelines. Clarithromycin MIC of 2 mg l À1 was considered susceptible and !8 mg l À1 was considered resistant. Inducible clindamycin resistance was defined as MIC 2 mg ml À1 after 3 days of incubation and !8 mg l À1 on day 14. Constitutive clarithromycin resistance was defined as MICs!8 mg l À1 at day 3 of incubation.
erm(41) and rrl were analysed for clarithromycin resistance contribution. Primers used for erm(41) and rrl gene amplification were as described [5, 6, 12] . Amplicon sequencing was performed and the presence of polymorphisms examined [11, 18] . For isolates that were found to exhibit constitutive resistance, full length rrl sequencing was also performed. The susceptibility of each subspecies was analysed using Fisher's exact test where a P-value of <0.05 indicated statistical significance.
From a retrospective collection of M. abscessus complex isolates, a total of 84 isolates were analysed ( Table 1 ). The proportion of isolates identified via sequencing of rpoB and hsp65 were as follows: M. massiliense (n=59), M. abscessus (n=20), and M. bolletii (n=5). A local observational cohort study involving clinical RGM isolates had previously indicated that the M. abscessus complex was the most frequently recovered species (74 %) in respiratory specimens [4] . However the composition of M. abscessus subspecies isolated was not known. Here, we show that M. massiliense was the dominant subspecies in our institution, accounting for approximately 70 % of the isolates. This was rather surprising as in different studies worldwide, even though the prevalence of each subspecies varied geographically, M. abscessus is usually prevalent and typically accounts for 51 to 78 % of the M. abscessus complex, followed by M. massiliense and M. bolletii [19] [20] [21] [22] [23] . And it was not unusual for study centers to not encounter M. bolletii [20, 21] .
Constitutive clarithromycin resistance, i.e. phenotypically observable resistance at day 3 of incubation, was only seen in 2 isolates, one M. abscessus and the other M. massiliense (Table 1) . Inducible resistance, recorded at day 14 of incubation, was evident in 18 isolates and not detected in M. massiliense. Overall, phenotypic clarithromycin resistance (inducible and constitutive) was detected in 34 % of all isolates (Tables 1 and 2 ). Within the subspecies, there were marked differences in the clarithromycin profiles with 98.3 % (58 out of 59) of M. massiliense isolates being susceptible in contrast to only 20 % of M. abscessus isolates (P<0.05). All isolates, regardless of subspecies, were fully resistant to Fluoroquinolone (Table 2) . And >85 % of the isolates remained susceptible to amikacin (Table 2 ).
Genotyping demonstrated 3 erm(41) genotypes: T28, C28 and deleted erm(41). Although alternative sequevars apart from these 3 are known to exist which can contribute with varying clarithromycin MICs, they were not observed in our study [18] . Only T28 and C28 sequevars were detected in M. abscessus and M. bolletii with full correlation between the polymorphisms and phenotypic clarithromycin sensitivity [24] . The T28 polymorphism was identified in 80 and 60 % of M. abscessus and M. bolletii, respectively. And the C28 polymorphism was detected in 20 and 40 % of M. abscessus and M. bolletii, respectively. All isolates with the T28 polymorphism had a clarithromycin MIC below the susceptible breakpoint at initial reading, but displayed inducible clarithromycin resistance by the end of the two-week incubation period. The presence of the C28 polymorphism resulted in clarithromycin-susceptibility of M. abscessus and M. bolletii isolates. All (100 %) of the M. massiliense isolates possessed truncated erm(41) which was characteristic of this subspecies [11] . Truncated erm (41) genes, though rare in non-M. massiliense isolates, have been detected [19] . M. massiliense may also gain clarithromycin resistance through the acquisition of full-length erm (41) [19, 24] however we did not encounter such isolates, instead the only clarithromycin resistance seen in M. massiliense was due to A2059G mutation in the rrl gene. The prevalence of M. massiliense is higher in our setting compared to other reports, with a truncated erm(41) gene consistently detected. As a result, clarithromycin remains a suitable treatment option for the majority of isolates.
rrl sequencing of clarithromycin-resistant isolates revealed the presence of point mutations A2508G and A2059G in 2 isolates (one M. abscessus, the other M. massiliense) which resulted in obvious clarithromycin resistance at day 3 of incubation. It is thought that macrolide-based chemotherapy selects for the emergence of high-level resistance through point mutations at positions 2058 and 2059 of the rrl gene [19, 25] . The two isolates bearing rrl mutations were from BAL specimens and it would have been interesting to see if the isolates bearing rrl mutations in our study came from patients undergoing macrolide therapy, however as we did not have ethics approval we were unable to review the patient treatment for these isolates. Recently, a new commercial kit the NTM-DR assay (Hain Lifescience, Nehren, Germany) was launched that detects both constitutive and acquired resistance mechanisms to macrolides. The assay has been reported to exhibit high sensitivity for the detection of M. abscessus complex isolates with rrl or rrs mutations [26] and attests to the increasing importance of molecular antimicrobial testing in NTM.
Chronic lung infections are the most common manifestation of infections by the M. abscessus complex. Commencing antibiotics immediately is not always necessary because of the chronicity of these infections. It is at times not unreasonable to await phenotypic susceptibility results prior to initiating treatment. With regards to rrl sequencing, turnaround time to reporting phenotypic constitutive clarithromycin is relatively fast, within three days. Further, constitutive clarithromycin resistance was uncommon in our setting (2.4 %). In this context, the value of rrl sequencing may debatable. However, with acute infections such as bacteraemia and meningitis (a rare disease manifestation), genotypic susceptibility testing should be initiated to accurately and rapidly determine susceptibility.
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